Gerstmann-Str€ aussler-Scheinker disease (GSS) is an autosomal, dominantly inherited prion disease. In this study, we present different complicated brain pathologies determined postmortem of monozygotic GSS twin sisters. Case 1 showed cerebellar ataxia at the age of 58 years, and died at 66 years. Case 2 became symptomatic at the age of 75 years, and died at 79 years. There was a 17-year difference in the age of onset between the twins. Postmortem examination revealed numerous prion protein (PrP) plaques in the brains of both cases. The spongiform change and brain atrophy in case 1 were more severe compared with those in case 2. Western-blot analysis identified proteinase-resistant PrP (PrP res ) at the molecular weight of 21-30 kDa and 8 kDa in the twins. Gel filtration revealed that PrP res was mainly composed of PrP oligomer. PrP res signal patterns were similar between the twins. Additionally, case 1 showed a-synucleinopathy and case 2 showed Alzheimer disease pathology. These different proteinopathies were involved in the amyloid plaque formations of both cases. The degree of GSS pathology was mainly related to disease duration. The amyloid plaque formations could be decorated by concomitant neuropathological changes such as a-synucleinopathy and tauopathy.
INTRODUCTION
Human prion diseases, including sporadic CreutzfeldtJakob disease (CJD), inherited prion diseases, and iatrogenic CJD, are fatal neurodegenerative disorders. GerstmannStr€ aussler-Scheinker disease (GSS) is an autosomal, dominantly inherited prion disease. There are many types of PRNP mutations associated with GSS, including P102L and P105L (1), A117V and G131V (2) , and Y145stop, F198S, and Q217R (3) (4) . GSS caused by the P102L point mutation (GSS P102L) is the second most common inherited prion disease in Japan (2014 Japanese CJD guidelines). The main features of GSS P102L are cerebellar ataxia and slowly progressive dementia; however, it is also generally accepted that its clinical symptoms are heterogeneous (4) (5) (6) . The pathological features of GSS are prion protein (PrP) amyloid plaque (PrP plaque). Hamasaki et al reported clinical discordance in GSS P102L Japanese monozygotic twins (7) . Case 1 showed gait disturbance and cerebellar ataxia at the age of 58 years, and died at the age of 66 years. Case 2 became symptomatic at the age of 75 years, and died at the age of 79 years. There was 17 years difference between the ages of onset in the twins. We performed postmortem examinations on both twins. There are very few reports on twins with prion diseases including GSS (7-9). Webb et al reported 2 pairs of GSS twins from central England (pair A and pair B) (8) . The report described a 7-year difference in the age of onset in the pair A monozygotic twins. For 1 of the twins (pair A, twin 1), postmortem examination was performed and many PrP plaques and type 1 PrP res and 8 kDa PrP res were found (8) . On the other hand, in pair B twins, detailed clinical and pathological features were not available (8; 9). As described earlier, large variance in age at onset was found in 2 of the 3 GSS twin pairs. It is currently considered that epigenetic factors may influence the difference in the age at onset; however, this has not been verified. In this report, we describe clinical and pathological discordance of monozygotic twins with GSS (case 1 and case 2). We also examined the PrP res pattern and the degree of polymerization of PrP and PrP res . This is the first report showing discordant pathological features in monozygotic twins with GSS.
MATERIALS AND METHODS

Clinical Summary
Case 1 (described as case II-4 in the previous paper) (7) . She showed gait disturbance and cerebellar incoordination in all extremities at the age of 58 years. Dementia and dysphagia developed at age 62 years. Transient myoclonus-like involuntary movements were noted in her legs. She was in akinetic mutism at age 62 years. EEG showed diffuse slowing and brain magnetic resonance imaging (MRI) revealed severe atrophy of the cerebral hemispheres, cerebellum, and pons. She died of aspiration pneumonia at age 66 years and had a postmortem examination. Genetic analysis demonstrated a P102L point mutation in PRNP. The polymorphic codon 129 was Met/Met and codon 219 was Glu/Glu.
Case 2 (II-5) (7). A P102L mutation was detected by genetic analysis. Monozygosity was confirmed by restriction fragment length polymorphism analysis of genomic DNA. She had never showed any neurological signs such as cerebellar symptoms or cognitive impairment before the age of 75 years. Ataxic gait and slurred speech were noted at the age of 75 years, 17 years after her twin became symptomatic. Dysesthesia and areflexia were noted in the lower limbs at age 76 years. Although MRI diffusion weighted imaging (DWI) showed no abnormal hyperintensities, hippocampal atrophy was demonstrated by VSRAD (Voxel-based Specific Regional analysis system for Alzheimer disease [AD]) (Z-score: 2.83). Dementia and dysphagia developed at age 77 years. She was in akinetic mutism at age 78 years. MRI showed mild brain atrophy, and DWI demonstrated bilateral abnormal hyperintensities in the cerebral neocortices. Single-photon computed tomography showed hypoperfusion in bilateral frontal and temporal (including hippocampus) lobes. She died of aspiration pneumonia at age 79 years and had a postmortem examination.
Family History
The twins' sister was the proband (II-8) (7). She showed unsteadiness at the age of 43 years. Ataxic gait and slurred speech slowly progressed with intellectual impairment. Her symptoms were similar to that seen in spinocerebellar degeneration. Marked hand tremors were also observed. EEG showed mild to moderate slowing in the frontal lobe with no paroxysmal synchronous discharge. Brain computed tomography showed moderate atrophy in the cerebellum and pons. She died of aspiration pneumonia at the age of 47 years. Necropsy revealed PrP plaques in the cerebral cortex (data not available). Gene analysis identified a point mutation in PRNP at codon 102 (P102L). The twin's father had unspecified gait disturbance; however, genetic analysis was not performed. The twin's mother had no symptoms. P102L mutation was not detected in the other members of the family (twin's 5 brothers and 1 sister) and none has symptoms.
Immunohistochemistry
Formalin-fixed tissues were pretreated with formic acid according to standard protocols. Brain tissues were harvested for analysis. Brain tissues included frontal cortex, temporal cortex, cingulate gyrus, parietal cortex, occipital cortex, basal ganglia, thalamus, hippocampus, amygdala, cerebellar cortex, midbrain, pons, and medulla oblongata. For histological examination, hematoxylin and eosin (H&E) staining, Klüver-Barrera staining and modified Bielschowsky method were performed. Immunohistochemistry was performed using a primary antibody specific to anti-PrP (mouse monoclonal 3F4 specific for PrP at 109-112, 1:400; Signet, Dedham, MA).
In addition, antiglial fibrillary acidic protein (rabbit polyclonal, 1:1000; Dako, Glostrup, Denmark), antiphosphorylated tau (mouse monoclonal AT8 specific for tau phosphorylated at Ser202/Thr205, 1:500; Innogenetics, Ghent, Belgium), anti-3 repeat tau (mouse monoclonal 8E6/C11, specific for tau at 267-316, 1:1000; Millipore, Billerica, MA), anti-4 repeat tau (mouse monoclonal 1E1/A6, specific for tau at 275-291, 1:200; Millipore), anti-b-protein (mouse monoclonal 6 F/3 D, specific for beta-protein at 8-17, 1:400; Dako), and antiphosphorylated a-synuclein (mouse monoclonal pSyn #64, specific for a-synuclein phosphorylated at Ser 129, 1:1000; Wako, Osaka, Japan) were used as primary antibodies. Sections were incubated with primary antibodies overnight at 4 C. After rinsing, immunoreaction products were detected by the polymer immunocomplex method using the Envision system (DakoCytomation, Glostrup, Denmark). Immunoreactivity was visualized using 3,3 0 -diaminobenzidine ([DAB], Dojindo, Kumamoto, Japan), and specimens were lightly counterstained with hematoxylin.
We performed double immunofluorescence with the following combinations of antibodies: rabbit monoclonal EP1802Y (specific for PrP at 212-230, 1:100; Abcam, Cambridge, UK) and mouse monoclonal b-protein, and EP1802Y and AT8. Alexa 488-labeled antirabbit IgG (Invitrogen, Carlsbad, CA) and Alexa 546-labeled antimouse IgG (Invitrogen) were used as secondary antibodies. The specimens were counterstained with 4 0 ,6-diamidino-2-phenlindole (Invitrogen) and visualized using a Nikon A1R-A1 confocal microscopy system (Nikon, Tokyo, Japan). All analyses were performed with the written consent of the patients and their family.
Molecular Characterization of PrP
Brain samples (frontal cortex) were frozen and stored at À80 C until use. The samples were homogenized to a final concentration of 10% in lysis buffer (100 mM Tris-HCl, 100 mM NaCl, 10 mM ethylenediaminetetraacetic acid, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, pH 7.6). To detect PrP res , the prepared homogenates were treated with 50 mg/mL proteinase-K (PK) for 1 hour at 37 C. Protease activity was then quenched by the addition of 1 mM Pefabloc SC (Roche, Indianapolis, IN). To detect PrP and PrP res , samples were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis in preparative gels (Any kD precast gel: Bio-Rad, Hercules, CA) and transferred onto polyvinylidene difluoride membranes. PrP C and PrP res were detected using an anti-PrP antibody (3F4). Peroxidase-conjugated antimouse IgG (AP192P, 1:3000, Chemicon, Temecula, CA) was used as the secondary antibody. The immunoreaction was visualized using the ECL Plus Western Blotting Detection System (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK). To detect oligomeric PrP, we used size-exclusion gel chromatography. Using the spin-column kit CHROMA SPIN-TE200 (Clontech, Mountain View, CA), the oligomeric PrP fraction was separated from the monomeric PrP fraction as previously described (10) (11) (12) (13) . Then, each fraction was treated with PK and the presence of PrP res was examined by Western blotting.
RESULTS
Pathological Findings
Case 1. At autopsy, the brain weighed 790 g with severe brain atrophy (Fig. 1A) . In coronal sections, thinned cerebral cortices and white matter degeneration were seen. Enlargement of the lateral ventricles was apparent (Fig. 1B) . Marked cerebellar atrophy was also noted (Fig. 1C) . The midbrain showed marked atrophy and the substantia nigra was depigmented (Fig. 1D) .
The results of histopathological examination are summarized in the Table with degeneration/deposits graded as: none, 0; mild, 1; moderate, 2; severe, 3. Microscopic examination demonstrated severe neuronal loss, gliosis, and rarefaction of neuropil across the cerebral cortices (Fig. 1E ). Amyloid plaques were observed by H&E staining (Fig. 1E, arrow) . White matter degeneration was also seen. Immunohistochemistry for PrP (3F4) revealed many PrP plaques (Fig. 1F) , whereas synaptic PrP deposits were not apparent. Spongiosis and neuronal loss were also severe in the putamen, globus pallidus, and thalamus. PrP deposits were evident in the globus pallidus, whereas they were very few in number in the putamen and thalamus. In the cerebellar cortices, the molecular layer was markedly thinned, and severe loss of Purkinje cells and granular cells was noted (Fig. 1G ). There were many PrP plaques both in the molecular layer (Fig. 1G, inset, Fig. 1H , inset) and the granular layer. The midbrain was severely affected (Fig. 1I ) and marked loss of melanin-containing neurons was also observed in the substantia nigra. There were many Lewy bodies in the substantia nigra (Fig. 1J) , whereas PrP deposits were mild. Immunohistochemistry for phosphorylated a-synuclein revealed Lewy bodies (Fig. 1K ) and Lewy neurites (Fig. 1L) in the substantia nigra, the dorsal nucleus of vagus, transentorhinal cortex, amygdala, frontal cortex, and temporal cortex. These pathological features correspond with a diffuse neocortex type of Lewy body pathology (14) . In addition, there were some dystrophic neurites immunopositive for phosphorylated a-synuclein around PrP plaques (Fig. 1M) . PrP plaques involving the a-synuclein-positive dystrophic neurites were rare in the frontal cortex: 0.37% (2/534) and in the temporal cortex: 0.78% (4/512). Immunohistochemistry for phosphorylated tau (AT8) revealed a small number of neurofibrillary tangles (NFT) in the hippocampus (Fig. 1N) , entorhinal cortex, and transentorhinal cortex, which correspond with NFT Braak stage III. In addition, dystrophic neurites immunopositive for phosphorylated tau were often found around PrP plaques in the hippocampus: 54.7% (123/225) (Fig. 1O) . Although numerous PrP plaques were noted throughout the cerebral neocortex, phosphorylated tau-immunopositive dystrophic neurites around PrP plaques were rarely seen in the cerebral neocortex in the frontal cortex: 1.87% (10/534) and in the temporal cortex: 5.66% (29/512). Immunohistochemistry for b-protein revealed no senile plaques (data not shown).
Case 2. Brain weighed 1170 g with mild cerebral and cerebellar atrophy ( Fig. 2A) . Mild hippocampal atrophy and mild enlargement of the lateral ventricles were observed (Fig. 2B) . Cerebellar atrophy was also mild (Fig. 2C) . The midbrain including the substantia nigra was preserved (Fig. 2D) .
Microscopic examination demonstrated moderate neuronal loss, gliosis, and spongiform change of the neuropil (Fig. 2E) in the cerebral neocortex. Spongiform change and gliosis were also found in the white matter. Immunohistochemistry for PrP (3F4) revealed many PrP plaques and PrP synaptic deposits (Fig. 2F ). Spongiosis and neuronal loss were also seen in the putamen, globus pallidus, and thalamus. PrP deposits were more apparent in the putamen and thalamus than in the globus pallidus. In the cerebellar cortices, the molecular layer was relatively preserved (Fig. 2G) . Mild neuronal loss of Purkinje cells and granular cells was seen (Fig. 2G) . PrP plaques were also seen (Fig. 2G, inset ). There were many PrP plaques, mainly in the granular layer (Fig. 2H) . The midbrain was preserved from atrophy, and the substantia nigra was well pigmented (data not shown). Immunohistochemistry for phosphorylated a-synuclein revealed no Lewy bodies in the brain, including in the substantia nigra and dorsal nucleus of the vagus (data not shown). Immunohistochemistry for phosphorylated tau (AT8) revealed many NFTs and neuropil threads in the cornu ammonis 1 region (Fig. 2I ). NFTs were equally immunopositive for 3-and 4-repeat tau (Fig. 2J, K) . NFTs and neuropil threads were also detected in the frontal neocortex (Fig. 2L) and in temporal and parietal neocortex. Thus, the NFT Braak stage corresponded to stage V (15). In addition, phosphorylated tau-immunopositive dystrophic neurites around PrP plaques were occasionally seen in the frontal cortex: 21.8% (99/454), the temporal cortex: 11.3% (41/362), and the hippocampus: 41.6% (42/101). Modified Bielschowsky's method and immunohistochemistry for b protein revealed numerous senile plaques in the cerebral cortices (Thal phase: 5, CERAD: frequent) (16) (Fig. 2M) . Double immunofluorescence for PrP and b protein showed various patterns. Multicentric PrP plaques (Fig. 3A-C ) and monocentric PrP plaques (Fig. 3D-F ) with no apparent immunoreactivity for b protein were frequently observed. PrP plaques accompanied with partial staining for b protein were occasionally observed in the frontal cortex: 27.3% (124/454) and in the temporal cortex: 9.67% (35/362) ( Fig. 3G-I ). There were several typical senile plaques containing a small amount of PrP (Fig.  3J-L ). There were a few PrP immunopositive plaques with a b protein core (Fig. 3M-O) .
Immunoblotting
Western-blot analysis using 3F4 showed type 1 PrP res and 8 kDa PrP res in both cases 1 and 2 (Fig. 4A ). An 8 kDa PrP res signal in case 1 was more intense than that in case 2 (Fig. 4A) . To detect oligomeric PrP, we performed size exclusion gel chromatography assays on samples from the frontal cortex. Oligomeric PrP was separated from monomeric PrP as previously described (11; 10-13) . Fractions 2-4 were considered oligomeric fractions, and fractions 7-9 were considered monomeric fractions. In case 1, without PK treatment, Western-blot analysis using 3F4 revealed intense PrP signals including low molecular PrP, mainly in oligomeric fractions 2-4 ( Fig. 4B) . In monomeric fractions 7-9, a weak normal pattern of 27-35 kDa PrP bands was detected, whereas the low molecular PrP signal was very faint. In case 2, intense PrP signals, including low molecular PrP, were noted mainly in oligomeric fractions 3 and 4 (Fig. 4C) . In monomeric fractions 7-9, a normal pattern of 27-35 kDa PrP bands was clearly detected, whereas the low molecular PrP signal was very faint. After PK treatment, type 1 PrP res and 8 kDa PrP res signals were noted mainly in oligomeric fractions both in case 1 (Fig. 4D ) and case 2 (Fig. 4E) . Conversely, in the monomeric fractions, PrP was almost completely digested, and the 8 kDa PrP res signal was very faint.
DISCUSSION
For the twins investigated in this study there was a 17-year difference in age of onset. Pathologically, case 1 showed GSS pathology concomitant with a-synucleinopathy, whereas b protein deposits were not found. Case 2 showed GSS pathology concomitant with AD pathology, including abundant tau deposits and numerous b protein deposits, whereas a-synucleinopathy was not found.
Although, variance in onset age and clinical symptoms are frequently found in GSS, the variance in age at onset in the present twins is surprisingly large. In Japan, age at onset of GSS P102L is 54.0 6 12.4 (22-75) (mean 6 SD [range] years) (17) . Case 2 showed the oldest onset age of GSS in Japan. In other monozygotic twins (pair A) from central England, there was a 7-year difference in the age at onset (8) . Unfortunately, detailed clinical data including onset age was not available for pair B. It is generally considered that epigenetic modifications after birth, resulting from environmental stimuli, may cause phenotypic variations in monozygotic twins (18) . Significantly reduced levels of DNA methylation were also observed in cerebral neocortex neuronal nuclei of an AD twin (19) . A longitudinal study of twin children showed that, between the ages of 5 and 10 years, there was divergence of methylation patterns due to environmental rather than genetic influences (20) . Therefore, it is possible that DNA demethylation of PRNP participated in disease onset in the present twins. Detailed data of the twins' life history were not recorded. The twins had lived together in their birthplace until the age of 20 years. Case 1 got married at the age of 20 years and she moved to another prefecture. Case 2 got married at the age of 23 years. She lived in the neighborhood of her birthplace and worked at a spinning factory from age 42 to 62 years. Although the twins may have experienced different environmental factors, it is difficult to determine the contributing factors to disease onset.
The degree of neurodegenerative changes in case 1 was more severe compared to that of case 2 (Table) , despite case 2 dying at an older age than case 1, and was concomitant with AD pathology. In case 1, PrP synaptic deposits were not as apparent in the cerebral cortex compared with case 2. In addition, the putamen and thalamus showed very severe neuronal loss and spongiosis; however, there were fewer PrP deposits compared with case 2. Case 1 had a longer disease duration (8 years) than that of case 2 (4 years). It is considered that extensive degenerative changes contributed inversely to PrP deposit density and that long disease duration contributes to the severity of GSS pathology. Western-blot analysis revealed an , was prominent in the oligomeric fractions in both cases. Although, oligomeric PrP is the most infectious unit with neurotoxic effects in prion diseases (21) (22) , no apparent differences in their signal patterns were noted.
Case 1 showed a-synucleinopathy including Lewy bodies, Lewy neurites, and dystrophic neurites around PrP plaques (Table) . The midbrain was atrophic and there were many Lewy bodies in the substantia nigra; however, symptoms of Parkinsonism such as resting tremor, bradykinesia, and rigidity were not observed in her clinical course. It could be considered that progression of the GSS symptoms made the Parkinsonism inconspicuous. Visual hallucination was not observed and a-synucleinopathy was mild in the cerebral neocortices. On the other hand, there was no a-synucleinopathy in case 2. Although, there are several reports of the coexistence of CJD and Lewy body disease (23) (24) (25) , there are few reports describing GSS concomitant with a-synucleinopathy (GSS F198S) (26) . In case 1, although the frequency was very low, a-synuclein-positive dystrophic neurites around PrP plaques were observed. It suggests a close relationship between a-synuclein and PrP. Recently, it was reported that normal cellular PrP binds to a-synuclein and facilitates a-synuclein spreading (27) . However, the precise relationships between phosphorylated a-synuclein and PrP plaque remain unclear. In case 2, there were no a-synuclein deposits. Therefore, we suggest that in this twin, epigenetic factors, such as oxidative stress, may relate to the onset of a-synucleinopathy rather than genetic factors. On the other hand, PrP plaques might be partly involved with a-synuclein dystrophic neurites.
In case 2, we observed widespread abnormal phosphorylated tau deposits, including NFTs and neuropil threads, throughout the cerebral cortices, corresponding to NFT Braak stage V. Widespread b protein deposits were also found (Thal phase: 5, CERAD: frequent) (Table) . These pathological findings were compatible with AD according to NIA-Alzheimer's Association (NIA-AA) guidelines. Although, dementia and hippocampal atrophy (VSRAD: Z-score: 2.83) were observed, AD was not diagnosed in her clinical course. Due to GSS's symptoms, clinical diagnosis of AD might have been difficult. On the other hand, in case 1, abnormal tau deposits were limited, corresponding to NFT Braak stage III. It is believed that abnormal tau phosphorylation is mainly involved in 2 processes: an aging and a b amyloid-based process. It seemed that the degree of tau deposits and b protein deposits were related to aging. On the other hand, tau dystrophic neurites around PrP plaques were observed in the twins, and case 1 showed tauopathy without b protein deposits. In addition, widespread tau pathology of particular cases of GSS (28) (29) and prion diseases with glycosylphosphatidylinositol anchor-lacking PrP (30-31) has been reported. On the other hand, it was reported that the frequency of tau pathologies is not unusually high in sporadic CJD (32) . Thus, these findings suggest that certain types of abnormal PrP aggregates could induce tau hyperphosphorylation probably distinct from aging and b amyloid-based process.
In case 2, immunohistochemistry also showed various patterns of relationship between PrP and b protein. Several recent papers have described the relationship between PrP and amyloid-b oligomers (33) (34) .
In conclusion, the difference in disease onset of GSS in the monozygotic twins was 17 years. Postmortem examination revealed concordant pathological findings. Case 1 showed GSS pathology with a-synucleinopathy, case 2 showed GSS pathology with AD pathology. It is considered that epigenetic factors play important roles in the disease onset of GSS and asynucleinopathy. In addition, our findings suggest that PrP plaques may be a factor involved in abnormal aggregation or abnormal phosphorylation of other proteins, such as tau and asynuclein. It is very important to investigate epigenetic factors such as CpG methylation status related to disease onset in GSS because GSS has a high disease penetration rate.
